Generation of biologically contained Ebola viruses.

Proceedings of the National Academy of Sciences of the United States of America
Peter HalfmannYoshihiro Kawaoka

Abstract

Ebola virus (EBOV), a public health concern in Africa and a potential biological weapon, is classified as a biosafety level-4 agent because of its high mortality rate and the lack of approved vaccines and antivirals. Basic research into the mechanisms of EBOV pathogenicity and the development of effective countermeasures are restricted by the current biosafety classification of EBOVs. We therefore developed biologically contained EBOV that express a reporter gene instead of the VP30 gene, which encodes an essential transcription factor. A Vero cell line that stably expresses VP30 provides this essential protein in trans and biologically confines the virus to its complete replication cycle in this cell line. This complementation approach is highly efficient because biologically contained EBOVs lacking the VP30 gene grow to titers similar to those obtained with wild-type virus. Moreover, EBOVs lacking the VP30 gene are indistinguishable in their morphology from wild-type virus and are genetically stable, as determined by sequence analysis after seven serial passages in VP30-expressing Vero cells. We propose that this system provides a safe means to handle EBOV outside a biosafety level-4 facility and will stimulate critical studi...Continue Reading

References

Feb 7, 1998·Proceedings of the National Academy of Sciences of the United States of America·A TakadaY Kawaoka
Nov 30, 2000·Proceedings of the National Academy of Sciences of the United States of America·R N HartyF P Hayes
May 3, 2001·Journal of Virology·L D JasenoskyY Kawaoka
Apr 23, 2002·Journal of Virology·Takeshi NodaYoshihiro Kawaoka
Jun 8, 2002·The Journal of Biological Chemistry·Jens ModrofStephan Becker
Feb 14, 2003·Journal of Virology·Jens ModrofElke Mühlberger
Dec 16, 2003·Proceedings of the National Academy of Sciences of the United States of America·Rekha G PanchalM Javad Aman
Mar 16, 2005·Journal of Virology·Allison GrosethRamon Flick
Mar 30, 2005·Journal of Virology·Balaji ManicassamyLijun Rong
Apr 16, 2005·Science·Kartik ChandranJames M Cunningham
Jul 30, 2005·Journal of Virology·Gabriele NeumannYoshihiro Kawaoka
May 25, 2006·Virology Journal·Reed F JohnsonRonald N Harty
Jul 14, 2006·Journal of Virological Methods·Sarah E McCarthyRonald N Harty
Jul 20, 2006·PLoS Pathogens·Hideki EbiharaYoshihiro Kawaoka
Sep 29, 2006·Journal of Virology·Masayuki ShimojimaYoshihiro Kawaoka

❮ Previous
Next ❯

Citations

Nov 22, 2011·Nature Structural & Molecular Biology·João M DiasErica Ollmann Saphire
Oct 19, 2011·The Journal of Infectious Diseases·Mathieu MateoViktor E Volchkov
Oct 19, 2011·The Journal of Infectious Diseases·Ayaka IwasaYoshihiro Kawaoka
Feb 13, 2009·Journal of Virology·Peter HalfmannYoshihiro Kawaoka
Oct 3, 2008·Journal of Virology·Miguel J MartínezViktor Volchkov
Dec 3, 2010·Journal of Virology·W W Shanaka I RodrigoLuis Martínez-Sobrido
May 10, 2013·Journal of Virology·Kei TakahashiYoshihiro Kawaoka
Oct 11, 2013·Journal of Virology·Lindsay Hill-BatorskiYoshihiro Kawaoka
Aug 30, 2014·Expert Review of Anti-infective Therapy·Thomas Hoenen, Heinz Feldmann
May 9, 2012·Expert Opinion on Biological Therapy·Thomas HoenenHeinz Feldmann
Feb 22, 2013·The Journal of General Virology·Jana Baron, Michael Baron
May 8, 2009·The Journal of Veterinary Medical Science·Akiko Makino, Yoshihiro Kawaoka
Mar 31, 2015·Science·Andrea MarziYoshihiro Kawaoka
Apr 29, 2015·Frontiers in Microbiology·Van Kinh NguyenEsteban A Hernandez-Vargas
Dec 21, 2014·Microbes and Infection·Ling Ye, Chinglai Yang
Jun 10, 2016·The Journal of Infectious Diseases·Danielle Westhoff SmithYoshihiro Kawaoka
Jun 28, 2016·Molecular Biology and Evolution·Michelle Kendall, Caroline Colijn
Jun 27, 2013·Biomacromolecules·Arcot R LokanathanJanne Laine
Apr 15, 2016·Expert Review of Vaccines·Chad E MireAndrea Marzi
Oct 21, 2016·Human Vaccines & Immunotherapeutics·Yuxiao WangFengcai Zhu
Feb 6, 2013·Scientific Reports·Asuka NanboYoshihiro Kawaoka
Jan 18, 2018·Proceedings of the National Academy of Sciences of the United States of America·Yuki TakamatsuStephan Becker
Feb 8, 2019·Journal of Virology·Lauren E WilliamsonJames E Crowe
Aug 2, 2019·PLoS Neglected Tropical Diseases·Peter J HalfmannFoday Sahr
Mar 1, 2014·Expert Review of Vaccines·Andrea Marzi, Heinz Feldmann
Mar 5, 2020·Expert Review of Vaccines·Kyle O'Donnell, Andrea Marzi
Jul 11, 2020·Biotechnology and Bioengineering·Randall AlfanoClaire Y-H Huang
Sep 12, 2018·Annual Review of Microbiology·Heinz FeldmannAndrea Marzi
Aug 28, 2018·Frontiers in Immunology·Kuldeep DhamaWanpen Chaicumpa
Dec 18, 2010·Expert Review of Vaccines·Darryl FalzaranoHeinz Feldmann
Apr 28, 2017·Virus Genes·Pierce Reynolds, Andrea Marzi
Jul 31, 2018·The Journal of Infectious Diseases·Peter HalfmannYoshihiro Kawaoka
Oct 20, 2018·Nature Immunology·Erica Ollmann SaphireGalit Alter
Oct 1, 2019·Annual Review of Virology·Wakako Furuyama, Andrea Marzi
Oct 8, 2019·Human Vaccines & Immunotherapeutics·John J Suschak, Connie S Schmaljohn
Jun 13, 2020·Nature Communications·Makoto KurodaYoshihiro Kawaoka

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.